Nurix Therapeutics, Inc. cash flow to debt ratio of -447.63% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Nurix Therapeutics, Inc.'s free cash flow has decreased 44.88% from $-181.86M last year to $-263.47M, signaling decreasing performance

Nurix Therapeutics, Inc.'s debt to equity ratio is 0.14, which means that the company's assets are healthy financed, signaling financial stability.

Nurix Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.05 last year to 0.14 today, signaling weakened financials

Nurix Therapeutics, Inc. has a net cash position, so leverage is healthy.

Nurix Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Nurix Therapeutics, Inc.'s profit margin has decreased (161.64%) in the last year from -354.85% to -928.44%, signaling decreasing performance

Nurix Therapeutics, Inc.'s short-term assets of $606.82M exceed its short-term liabilities of $86.47M

Nurix Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Nurix Therapeutics, Inc.'s return on equity of -76.09%, is lower than 15.00%, indicating bad performance

Nurix Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Nurix Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Nurix Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Nurix Therapeutics, Inc. has negative free cash flow, indicating cash burn

Nurix Therapeutics, Inc.'s yearly earnings has decreased 36.62% since last year from $-193.57M to $-264.46M, signaling decreasing performance

Nurix Therapeutics, Inc.'s yearly revenue has increased 53.95% since last year from $54.55M to $83.98M, signaling increasing performance

ROIC -77.32% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Nurix Therapeutics, Inc.'s 3-year revenue CAGR of 29.55% is positive, indicating growing revenue over the past 3 years

Nurix Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Nurix Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Nurix Therapeutics, Inc. has insufficient data to evaluate this check.

Nurix Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nurix Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Nurix Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Nurix Therapeutics, Inc. is overvalued relative to its fair value price of -73.24 based on Earnings Fair Value model

Nurix Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nurix Therapeutics, Inc. has a price-to-book ratio of 7.14x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Nurix Therapeutics, Inc. has a price-to-sales ratio of 78.19x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue